Liraglutide Treatment in a Patient With HIV and Uncontrolled Insulin-Treated Type 2 Diabetes

Combination antiretroviral therapy has improved survival in human immunodeficiency virus (HIV)-infected patients but has become associated with altered body fat distribution, type 2 diabetes, and increased cardiovascular risk (1). Both the protease inhibitors and nucleotide reverse transcriptase inhibitors have been implicated (1). Management of HIV-associated type 2 diabetes may be challenging because of severe insulin resistance, which—in spite of the initial use of insulin sensitizers—often requires a high dose of insulin, causing additional weight gain (1). The glucagon-like peptide-1 receptor agonists lower glucose, reduce weight, and improve the cardiovascular risk profile in type 2 diabetes (2,3). Recently, exenatide use in an HIV-associated type 2 diabetic case and in a type 1 diabetic HIV patient was reported (4,5). Here, we report the first successful liraglutide …